ACE2 and COVID-19: Specifically, Metformin treatment–associated ACE2 expression and stability can positively modulate the beneficial arm (ACE2/Ang 1–7) of the RAAS and prevent pancreatic damage and new-onset diabetes in COVID-19 patients by protecting and maintaining the normal function of the pancreas [81].